Skip to main content

This job has expired

You will need to login before you can apply for a job.

Senior Director, Pharmacometrician

Employer
Molecular Templates, Inc.
Location
Working From Home
Start date
Oct 10, 2021

View more

Discipline
Engineering, Biomedical Engineer, Science/R&D, Pharmacology
Required Education
Doctorate/PHD/MD
Position Type
Full time

Job Details

Molecular Templates is a clinical-stage biopharmaceutical company focused on the discovery and development of differentiated, targeted, biologic therapeutics.  Our proprietary biologic drug platform technology, known as engineered toxin bodies, or ETBs, leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer and other serious diseases.  MTEM currently has multiple clinical-stage ETB candidates in development including MT-5111, MT-0169, and MT-6402.  Additional preclinical compounds derived from our ETB platform technology are being advanced toward clinical development.  Additional information about Molecular Templates can be obtained at www.mtem.com.

 

Position Overview:


The Clinical Development department at Molecular Templates is seeking a Head of Pharmacometrics with exceptional technical and leadership skills to develop and implement modeling and simulation strategies to advance development of novel oncology drug candidates (engineered toxin bodies) across various stages of preclinical and clinical development. This individual will be responsible for the development and implementation of modeling and simulation strategies to ensure that the appropriate dose, route, and schedule of ETB’s is delivered by integrating data from within the department and in collaboration with the Research and Development departments.


Job Responsibilities:

 

  • Work in close collaboration with key stakeholders, including preclinical toxicology, clinical development, and tumor immunology to define and execute clinical pharmacology and M&S strategy for novel oncology drug candidates
  • Represent the clinical pharmacology function on development project teams and take accountability for clinical pharmacology deliverables including sample schedule, collection, storage, analysis, and interpretation
  • Conduct PK/PD and exposure-response analyses using pharmacostatistical and relevant state-of-the-art modeling and simulation techniques to support dose selection, trial design, Go/No-Go decisions, regulatory submission documents, and publications
  • Provide subject matter expertise to inform decisions on key scientific questions
  • Provide key guidance on regulatory strategies, and present data and interpretations in written and oral form to regulatory bodies to enable optimal clinical development and registration of novel drugs
  • Manage relationships with all external vendors involved in PK sample collection and analysis
  • Interface with clinical trial sites to train the site staff on appropriate sample collection and storage
  • Mentor and supervise junior staff members, if required
  • Represent MTEM in the external scientific environment, influencing partners and regulators in a positive way
  • Actively participate in departmental leadership
  • Build collaborative networks internal and external to the company to ensure rapid and successful development of novel drugs

 

 

Qualifications:
 

  • An advanced degree (PhD, MD, or PharmD) with ten+ (10) years of experience in Pharmacology, Pharmaceutical Sciences, Pharmacy, Biomedical Engineering, or other related fields
  • Expertise in Quantitative Pharmacology and hands-on modeling and simulation skills using NONMEM, R, Simcyp, SAS, MATLAB and/or other modeling and simulation software
  • Experience with advanced mechanistic PK/PD models, disease models, PBPK models, Quantitative System Pharmacology (QSP) models, clinical trial simulation is highly preferred
  • Track record of working with health authorities and responding to regulatory questions
  • Knowledge of global regulatory requirements and guidances on quantitative analyses
  • Excellent interpersonal, verbal and written English communication skills and the ability to function in a highly matrixed team environment
  • Previous record of impact on drug development through quantitative approaches with strong leadership skills and the ability to influence
  • Substantial understanding of oncology or related field (e.g., inflammation, immunology)
  • Experience with large molecule therapeutics is preferred

 

Reporting Structure:

This position currently has no supervisory responsibilities.  This position reports to VP, Immunology

 

 

Molecular Templates celebrates and supports our differences and is proud to be an Equal Employment Opportunity employer.  We do not discriminate based upon race, religion, color, national origin, sex (including pregnancy, childbirth, or related medical conditions), sexual orientation, gender identity, gender expression, age, veteran status, disability, or any other legally protected characteristic.  

MTEM is committed to providing reasonable accommodations for qualified individuals.  If you need assistance with your application due to a disability, you may contact us at: careers@mtem.com.

By submitting a resume for consideration, applicants verify that they have read MTEM’s Applicant Privacy notice. https://www.mtem.com/privacy-policy

Company

Molecular Templates, Inc. (MTEM) is a clinical stage biopharmaceutical company focused on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform with unique mechanisms of actions which are highly differentiated from antibody drug conjugates (ADCs). MTEM is developing MT-6402, which is in a Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients; MT-5111, which is in a Phase I clinical trial for the treatment of HER2-positive cancers; and MT-0169, which is in a Phase I clinical trial to treat relapsed/refractory myeloma. Additional preclinical compounds derived from our ETB platform technology are being advanced toward clinical development.  Additional information about MTEM can be obtained at www.mtem.com.  

OWNERSHIP: Public

STOCK SYMBOL: MTEM

STOCK EXCHANGE: NASDAQ

Company info
Website
Phone
512-869-1555
Location
9301 Amberglen Blvd, Ste 100
Austin
TX
78729
US

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert